Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Systemic Inflammatory and Metabolic Biomarkers of Peri-Implant Diseases in Postmenopausal Women

16. November 2026 aktualisiert von: Kübra Hazal Bilgin

Systemic Inflammatory and Metabolic Determinants of Peri-Implant Diseases in Postmenopausal Women: A Multidimensional Risk Assessment

Peri-implant diseases are inflammatory conditions affecting the tissues surrounding dental implants. Peri-implant mucositis involves inflammation of the soft tissues, whereas peri-implantitis is characterized by inflammation accompanied by progressive supporting bone loss. Hormonal, metabolic, and inflammatory changes associated with menopause may influence peri-implant tissue health.

This observational, cross-sectional study aims to investigate the associations of serum homocysteine, vitamin B12, folate, 25-hydroxyvitamin D, and the systemic immune-inflammation index (SII) with peri-implant health and disease status in postmenopausal women.

Approximately 120 postmenopausal women aged 45-70 years with at least one functional dental implant will be included. Participants will be classified into three groups based on clinical and radiographic examinations: peri-implant health, peri-implant mucositis, and peri-implantitis.

Blood samples will be collected to measure homocysteine, vitamin B12, folate, 25-hydroxyvitamin D, and follicle-stimulating hormone (FSH). FSH will be used to support the assessment of postmenopausal status. The SII will be calculated from neutrophil, lymphocyte, and platelet counts obtained from complete blood count measurements.

Periodontal and peri-implant risk profiles will be evaluated using Periodontal Risk Assessment (PRA) and Implant Disease Risk Assessment (IDRA). Associations between systemic biomarkers, clinical and radiographic parameters, and individual risk profiles will be statistically analyzed.

The findings may contribute to a better understanding of the systemic metabolic and inflammatory characteristics associated with peri-implant diseases in postmenopausal women and provide preliminary data for future longitudinal studies.

Studienübersicht

Status

Rekrutierung

Bedingungen

Detaillierte Beschreibung

Peri-implant diseases are inflammatory conditions affecting the tissues surrounding dental implants and are associated with interactions between microbial biofilms and host immune-inflammatory responses. Peri-implant mucositis is characterized by inflammation confined to the peri-implant soft tissues, whereas peri-implantitis involves inflammation accompanied by progressive loss of supporting bone. Menopause is associated with hormonal, metabolic, and immunological changes that may influence bone metabolism, systemic inflammation, and peri-implant tissue health. Homocysteine is involved in metabolic pathways associated with oxidative stress, inflammation, and bone metabolism. Vitamin B12 and folate play essential roles in homocysteine metabolism, while vitamin D contributes to bone homeostasis and immune regulation. The systemic immune-inflammation index (SII), calculated from neutrophil, lymphocyte, and platelet counts, provides a composite measure of systemic inflammatory status. However, evidence regarding the associations of these systemic biomarkers with peri-implant diseases in postmenopausal women remains limited.

The primary objective of this study is to compare serum homocysteine, vitamin B12, folate, 25-hydroxyvitamin D, and SII among postmenopausal women with peri-implant health, peri-implant mucositis, and peri-implantitis. Secondary objectives are to investigate the associations between these biomarkers and clinical and radiographic peri-implant parameters and to evaluate their relationships with individual periodontal and peri-implant risk profiles assessed using Periodontal Risk Assessment (PRA) and Implant Disease Risk Assessment (IDRA).

This single-center, analytical, observational, cross-sectional clinical study will include approximately 120 postmenopausal women aged 45-70 years with at least one functional dental implant. The target sample consists of approximately 40 participants in each of three groups: peri-implant health, peri-implant mucositis, and peri-implantitis. Postmenopausal status will be assessed based on at least 12 months of amenorrhea and/or serum follicle-stimulating hormone (FSH) levels consistent with menopause (≥40 IU/L). Eligible implants must have completed prosthetic rehabilitation and have been in function for at least one year. Participants will be classified according to the 2017 World Workshop classification of periodontal and peri-implant diseases and conditions, using clinical and radiographic findings. Peri-implant health will be defined by the absence of clinical inflammation and pathological supporting bone loss. Peri-implant mucositis will be characterized by peri-implant soft tissue inflammation without progressive supporting bone loss, whereas peri-implantitis will involve inflammatory findings accompanied by progressive supporting bone loss. When baseline radiographs are unavailable, the relevant consensus-based clinical and radiographic case definitions will be applied.

Only one index implant per participant will be included in the primary analyses to avoid clustering effects. Whenever possible, functional implants with single-crown restorations that are not splinted to adjacent implants will be preferred. When multiple eligible implants are present, the implant showing the most pronounced clinical and radiographic disease findings will generally be selected. In participants with peri-implant health, a predefined standardized selection procedure will be applied, with random selection among similarly eligible implants when necessary. Implant location, functional duration, placement and loading characteristics, restoration type, and other available implant-related factors will be recorded.

Full-mouth periodontal examinations will include plaque assessment, probing depth, bleeding on probing, clinical attachment level, gingival recession, gingival phenotype, and keratinized gingival width. Furcation involvement and tooth mobility will be recorded where applicable. At the index implant, plaque, probing depth, bleeding on probing, and suppuration will be assessed at six sites. Keratinized mucosal width, peri-implant mucosal phenotype, mucosal recession, and implant mobility will also be evaluated. Standardized digital periapical radiographs will be used to measure mesial and distal marginal bone levels relative to a fixed implant reference point. Radiographic measurements will be calibrated using known implant dimensions. Available appropriate radiographs of natural teeth will be used for periodontal bone loss-to-age assessments when required.

Venous blood samples will be collected during the clinical assessment period. Serum homocysteine, vitamin B12, folate, 25-hydroxyvitamin D, and FSH levels will be measured using validated laboratory procedures. Homocysteine analysis will be performed by an external laboratory, whereas the remaining biochemical and hematological parameters will be assessed through the participating institution's clinical laboratory services. Complete blood count measurements will provide neutrophil, lymphocyte, and platelet counts. The systemic immune-inflammation index will be calculated by multiplying the platelet count by the neutrophil count and dividing the result by the lymphocyte count. Homocysteine levels will be evaluated in conjunction with vitamin B12 and folate concentrations to characterize the homocysteine-B12-folate metabolic axis. FSH will be used to support the assessment of postmenopausal status rather than as a primary peri-implant disease biomarker.

Individual periodontal risk profiles will be assessed using PRA, incorporating bleeding on probing, residual periodontal pockets, tooth loss, periodontal bone loss relative to age, and relevant systemic and environmental risk factors. Peri-implant disease risk profiles will be evaluated using IDRA, considering periodontal history, clinical findings, supportive periodontal care attendance, and implant- and prosthesis-related factors. Participants will be classified into low-, moderate-, or high-risk categories according to the respective assessment frameworks. PRA and IDRA will be used as complementary tools representing periodontal disease progression risk and implant-specific disease risk, respectively.

Continuous biomarker values will be compared among the three peri-implant groups using appropriate parametric or nonparametric statistical methods according to data distribution and variance assumptions. Associations between systemic biomarkers, clinical and radiographic parameters, and risk assessment results will be investigated using correlation analyses. Where sample size and outcome frequencies permit, multinomial logistic regression will be used to investigate factors independently associated with the three-category peri-implant clinical phenotype. Binary logistic regression may be performed for analyses considering the presence of peri-implantitis as a dichotomous outcome. Potential confounding factors, including age, menopause duration, systemic conditions, medication use, periodontal history, implant function duration, supportive care attendance, and implant-related characteristics, will be considered as appropriate. Exploratory receiver operating characteristic analyses may be performed for selected biomarkers, particularly homocysteine and SII. Any potential thresholds will be interpreted as hypothesis-generating findings rather than validated diagnostic cutoffs.

This study aims to improve understanding of the systemic metabolic and inflammatory characteristics associated with peri-implant health and disease in postmenopausal women. The findings may contribute to a more comprehensive evaluation of the multifactorial nature of peri-implant diseases and provide preliminary evidence for future larger-scale and longitudinal investigations. Given the observational, cross-sectional design, no causal or prognostic conclusions will be drawn.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

120

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Istanbul, Türkei (türkiye)
        • Rekrutierung
        • Istanbul Medipol University Hospital
        • Kontakt:
        • Hauptermittler:
          • Hilal Uslu Toygar, DDS, PhD
        • Unterermittler:
          • Kübra Hazal Bilgin, DDS
        • Unterermittler:
          • Merve Can, DDS

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

45 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population will consist of postmenopausal women aged 45-70 years attending Istanbul Medipol University dental clinics who have at least one functional dental implant loaded for at least one year. Eligible participants will be recruited from the clinical population and classified into peri-implant health, peri-implant mucositis, or peri-implantitis groups according to clinical and radiographic findings based on the 2017 World Workshop classification. Approximately 120 participants will be included, with a target of 40 participants per group.

Beschreibung

Inclusion Criteria:

  • Female participants aged 45-70 years.
  • Postmenopausal status defined by at least 12 months of amenorrhea and/or serum follicle-stimulating hormone (FSH) levels consistent with menopause (≥40 IU/L).
  • Presence of at least one functional dental implant.
  • Completed and functional implant-supported prosthetic restoration.
  • Implant in function for at least one year following prosthetic loading.
  • Eligibility for clinical periodontal and peri-implant examination and radiographic assessment.
  • Willingness to participate and provision of written informed consent.

Exclusion Criteria:

  • Current active smoking.
  • Uncontrolled systemic diseases.
  • Systemic antibiotic use or regular systemic anti-inflammatory medication use within the previous three months.
  • Use of vitamin B12, folic acid/folate, or supplements directly affecting homocysteine metabolism within the previous three months.
  • Current hormone replacement therapy, antiresorptive therapy, immunosuppressive therapy, or chemotherapy.
  • History of radiotherapy to the head and neck region.
  • Systemic or local conditions that may substantially compromise the reliability of clinical or laboratory measurements.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: CROSS_SECTIONAL

Kohorten und Interventionen

Gruppe / Kohorte
Peri-Implant Health

Postmenopausal women aged 45-70 years with at least one functional dental implant and no clinical signs of peri-implant inflammation, bleeding on probing, suppuration, or pathological supporting bone loss at the index implant. Participants will undergo periodontal and peri-implant examinations, radiographic assessment, blood biomarker measurements, and PRA and IDRA evaluations. Approximately 40 participants are planned for this group.

Peri-Implant Mucositis

Postmenopausal women aged 45-70 years with at least one functional dental implant showing peri-implant soft tissue inflammation, characterized by bleeding on probing and/or suppuration, without progressive pathological supporting bone loss at the index implant. Participants will undergo periodontal and peri-implant examinations, radiographic assessment, blood biomarker measurements, and PRA and IDRA evaluations. Approximately 40 participants are planned for this group.

Peri-Implantitis

Postmenopausal women aged 45-70 years with at least one functional dental implant showing peri-implant inflammation accompanied by progressive supporting bone loss, consistent with the 2017 World Workshop case definition of peri-implantitis. Participants will undergo periodontal and peri-implant examinations, radiographic assessment, blood biomarker measurements, and PRA and IDRA evaluations. Approximately 40 participants are planned for this group.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Serum Homocysteine Level
Zeitfenster: At baseline (single study visit)

Serum homocysteine concentration will be measured in µmol/L using validated laboratory procedures. Homocysteine levels will be compared among postmenopausal women with peri-implant health, peri-implant mucositis, and peri-implantitis.

At baseline (single study visit)
Serum Vitamin B12 Level
Zeitfenster: At baseline (single study visit)

Serum vitamin B12 concentration will be measured in pg/mL and compared across the three peri-implant groups.

At baseline (single study visit)
Serum Folate Level
Zeitfenster: At baseline (single study visit)

Serum folate concentration will be measured in ng/mL and compared across the three peri-implant groups.

At baseline (single study visit)
Serum 25-Hydroxyvitamin D Level
Zeitfenster: At baseline (single study visit)

Serum 25-hydroxyvitamin D concentration will be measured in ng/mL and compared across the three peri-implant groups.

At baseline (single study visit)
Systemic Immune-Inflammation Index (SII)
Zeitfenster: At baseline (single study visit)

SII will be calculated as platelet count multiplied by neutrophil count divided by lymphocyte count, using complete blood count parameters, and compared across the three peri-implant groups.

At baseline (single study visit)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Periodontal Risk Assessment (PRA) Category
Zeitfenster: At baseline (single study visit)

Participants will be classified into low, moderate, or high periodontal risk categories using the Periodontal Risk Assessment framework.

At baseline (single study visit)
Implant Disease Risk Assessment (IDRA) Category
Zeitfenster: At baseline (single study visit)

Participants will be classified into low, moderate, or high peri-implant disease risk categories using the Implant Disease Risk Assessment framework.

At baseline (single study visit)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Oktober 2026

Primärer Abschluss (Geschätzt)

1. Mai 2027

Studienabschluss (Geschätzt)

1. August 2027

Studienanmeldedaten

Zuerst eingereicht

16. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

16. November 2026

Zuerst gepostet (Tatsächlich)

20. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 1397-10.09.2026
  • BAP 2026-71 (Andere Zuschuss-/Finanzierungsnummer: Istanbul Medipol University)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .